Within the context of clinical trials, the section evaluates methodological issues relevant to both research and treatment, for example innovations in drug monitoring. In one study, sweat and urine specimens were collected from 44 methadone-maintenance patients to monitor cocaine use. Paired sweat patches that were applied and removed weekly (Tuesday) were compared to urine specimens collected Wednesday, Friday and Monday. Sweat patches were analyzed for cocaine, benzoylecgonine (BZE), and ecgonine methyl ester (EME); all patches (N=930) were analyzed by ELISA immunoassay (cutoff concentration 10 ng/ mL), and a subset of patches (N = 591) were also analyzed by GC-MS (cutoff concentration 5 ng/mL). Urine specimens were analyzed qualitatively for BZE by EMIT (cutoff 300 ng/mL), and a subset were also analyzed semiquantitatively for BZE by FPIA (LOD = 30 ng/mL) and quantitatively for cocaine by GC-MS (LOD = 5 ng/mL). Results were evaluated to: 1) determine the relative amounts of cocaine and its metabolites in sweat; 2) assess replicability in duplicate sweat patches; 3) compare ELISA and GC-MS results for cocaine in sweat; and 4) compare the detection of cocaine use by sweat and urine testing. Cocaine was detected by GC-MS in 99% of ELISA-positive sweat patches; median concentrations of cocaine, BZE, and EME were 393, 79, and 74 ng/mL. There was good replication of results in duplicate patches. The sensitivity, specificity, and efficiency of sweat ELISA cocaine results compared to sweat GC-MS results were 93.1%, 90.5%, and 93.5%. The sensitivity, specificity, and efficiency of sweat ELISA results for cocaine compared to urine EMIT results were 97.6%, 60.5%, and 77.7%. These findings support the utility of sweat patches for monitoring cocaine use, though further evaluation is needed. (Preston KL, Huestis MA, Wong CJ, Umbricht A, Goldberger BA, and Cone EJ. Monitoring cocaine use in sweat and urine of substance abuse treatment patients. Journal of Analytical Toxicology 23: 313-322, 1999.) - outcome predictor, cocaine, drug use monitoring, urinalysis, substance abuse, substance abuse treatment, sweat - Human Subjects

Agency
National Institute of Health (NIH)
Institute
National Institute on Drug Abuse (NIDA)
Type
Intramural Research (Z01)
Project #
1Z01DA000234-07
Application #
6289597
Study Section
Special Emphasis Panel (CPTR)
Project Start
Project End
Budget Start
Budget End
Support Year
7
Fiscal Year
1999
Total Cost
Indirect Cost
Name
National Institute on Drug Abuse
Department
Type
DUNS #
City
State
Country
United States
Zip Code
Kowalczyk, William J (2017) The utility of geographically-explicit ecological momentary assessment: from description to intervention. Soc Psychiatry Psychiatr Epidemiol 52:131-133
Ghitza, Udi E; Epstein, David H; Preston, Kenzie L (2008) Self-report of illicit benzodiazepine use on the Addiction Severity Index predicts treatment outcome. Drug Alcohol Depend 97:150-7
Ghitza, Udi E; Epstein, David H; Preston, Kenzie L (2007) Psychosocial functioning and cocaine use during treatment: strength of relationship depends on type of urine-testing method. Drug Alcohol Depend 91:169-77
Heinz, Adrienne; Epstein, David H; Preston, Kenzie L (2007) Spiritual/Religious experiences and in-treatment outcome in an inner-city program for heroin and cocaine dependence. J Psychoactive Drugs 39:41-9
Ghitza, Udi E; Epstein, David H; Preston, Kenzie L (2007) Nonreporting of cannabis use: Predictors and relationship to treatment outcome in methadone maintained patients. Addict Behav 32:938-49
Epstein, David H; Preston, Kenzie L; Jasinski, Donald R (2006) Abuse liability, behavioral pharmacology, and physical-dependence potential of opioids in humans and laboratory animals: lessons from tramadol. Biol Psychol 73:90-9
Heinz, Adrienne J; Epstein, David H; Schroeder, Jennifer R et al. (2006) Heroin and cocaine craving and use during treatment: measurement validation and potential relationships. J Subst Abuse Treat 31:355-64
Schroeder, Jennifer R; Epstein, David H; Umbricht, Annie et al. (2006) Changes in HIV risk behaviors among patients receiving combined pharmacological and behavioral interventions for heroin and cocaine dependence. Addict Behav 31:868-79
Carroll, C Patrick; Walsh, Sharon L; Bigelow, George E et al. (2006) Assessment of agonist and antagonist effects of tramadol in opioid-dependent humans. Exp Clin Psychopharmacol 14:109-20
Schroeder, Jennifer R; Schmittner, John P; Epstein, David H et al. (2005) Adverse events among patients in a behavioral treatment trial for heroin and cocaine dependence: effects of age, race, and gender. Drug Alcohol Depend 80:45-51

Showing the most recent 10 out of 32 publications